Delivery Order SPE2DB20D9127-SPE2DB25FPRA8
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $118,467.44 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 3,750 units of Asparlas 5 ml vials. The contract is firm fixed-price with an ultimate completion date of September 17, 2025. This delivery order was issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA under the SPE2DB program, a $499.999 billion vehicle that...
- The Defense Logistics Agency awarded a delivery order valued at $148,084.30 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 3,750 units of Asparlas 5 milliliter vials. This firm fixed-price delivery order is expected to reach completion by August 29, 2025, and represents a continuation of the companies' ongoing pharmaceutical supply relationship. The award carries no set-aside designation, indicating that DMS...
- The Defense Logistics Agency awarded a $148,084.30 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, on July 17, 2025. The delivery order calls for 3,750 units of Asparlas (5 ML vials) with a completion date of August 7, 2025. This firm fixed-price contract contains no set-aside designation, allowing DMS Pharmaceutical Group to compete directly in the open market despite its small business status. The award...
- The Defense Logistics Agency awarded a delivery order valued at $148,084.30 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of 3,750 units of Asparlas (5 ml vials). The contract is firm fixed-price with an ultimate completion date of September 23, 2025, and was awarded on September 2, 2025. This delivery order was issued without a set-aside designation, allowing the vendor to compete directly in the federal...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency valued at $148,084.30 for 3,750 units of Asparlas (5 milliliter vials). The contract, issued on August 15, 2025, with an ultimate completion date of September 8, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on July 31, 2025, with a ceiling value of $29,616.86 for the supply of 3,750 units of Asparlas 5 ML vials. Asparlas is a leukemia treatment medication, and this delivery order will be fulfilled from DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA under the SPE2DB program, a comprehensive pharmaceutical supply agreement valued at $499,999,999 and valid through November...
- On August 21, 2025, the Defense Logistics Agency awarded a firm fixed-price delivery order valued at $59,233.74 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order calls for 3,750 units of Asparlas (5 mL vials) to be delivered by September 12, 2025. This award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis. Asparlas is a pediatric acute lymphoblastic...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $110,459.16 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of 3,750 units of the 5 ML ASPARLAS (asparaginase erwinia chrysanthemi) vial to support the medical needs of military healthcare facilities. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $59,233.74 by the Defense Logistics Agency on September 10, 2025. The delivery order, with an ultimate completion date of October 1, 2025, calls for the supply of 3,750 units of Asparlas in 5 milliliter vials. This award was issued without a set-aside designation and represents a specific product delivery under DMS...
- This firm fixed-price delivery order, valued at $248,533.02, was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, which has a completion date of May 6, 2024, is for the delivery of 3,750 units of the oncology drug ASPARLAS in 5 mL vials. DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999,...
- SPE2DB20D9127Indefinite Delivery Contract
- SPE2DB20D9127-SPE2DB25FPRA8Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of 3,750 units of Asparlas 5 mL vials. The contract, valued at $59,233.74, is structured as a firm fixed-price delivery order with an ultimate completion date of August 22, 2025. This award was issued without set-aside designation, allowing DMS Pharmaceutical Group to compete directly in the federal marketplace. The place of performance is Park Ridge, Illinois. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $499.999 billion vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products supporting medical supply needs of military health facilities worldwide. As a critical supplier in the federal pharmaceutical supply chain, DMS Pharmaceutical Group routinely delivers prescription medications, biologics, and medical consumables to Department of Defense healthcare sites across the nation. Asparlas (calaspargase pegol-mknl) is an oncology medication used in leukemia treatment protocols, reflecting the company's portfolio of specialized pharmaceutical products for military medical facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $59.2k | 8/1/25 |